For pharmaceutical companies, health insurance directory changes largely affect the sales of the drug and the development of the enterprise. Now believes it has clinical value of innovative medicine, medical insurance directory of drugs into many provinces and cities, or into the drugs of all kinds of medical treatment guidelines or major disease treatment to enter the new medical insurance directory the possibility of more.
Has been more than 20 provinces and cities in most of the medical insurance directory of 20 varieties is auxiliary and monitored the kinds, including six exclusive varieties. In the face of these varieties for further analysis.
Table 1.20 many provinces and cities in medical insurance directory of varieties in the size of the market ($one hundred million)
The nervous system drugs
Olathe temple
Olathe temple is the nervous system drugs, belongs to the brain metabolism improve agent, suitable for mild-to-moderate vascular dementia, senile dementia and brain injury caused by memory and mental retardation. In recent years, with China's aging population growth trend, the nervous system class market is rising.
In 2015, according to kang CMH monitoring data show that in nervous system drugs market growth rate of 4.16%. Olathe in one second. In 2013-2015 "olathe drug market has kept rising, compound annual growth rate of 9.24%. The size of the market in 2015 up to 3.531 billion yuan, a year-on-year growth of 5.35% in 2014. At present the main manufacturer for domestic enterprises, market share ranking the first in 2015 is the guangdong letter pharmaceutical market share (46.22%), next to the joint pharmaceutical market share (28.27%), nolato, group (21.37%), etc.
Brain protein hydrolysate
Brain protein hydrolysate is one of the typical "magic pill", the use of large, attracted a lot of manufacturers, occurred many times in recent years in some provinces auxiliary medication and monitored list. 2015 brain protein hydrolysate was ranked no. 7 in the nervous system drugs, market size is 3.821 billion yuan, slowing growth. Greater competition in the drug market, major manufacturers have yunnan union pharmaceutical market share (28.91%), ha sanlian pharmaceutical market share (19.31%), shanxi buder pharmaceutical market share (16.69%) and lung fu pharmaceutical industry (12.26%), etc.
Brain glycosides carnosine
Brain glycosides carnosine is used in the treatment of stroke, dementia, neonatal hypoxic ischemic encephalopathy, traumatic brain injury, spinal cord injury and other central nervous system injury caused by traumatic and peripheral nerve injury, etc.
2015 brain glycosides carnosine drug market size is 1.814 billion yuan, down 28.55% year-on-year in 2014. Sihuan pharmaceutical of occupied more than 99% of the market share.
The cardiovascular system and medical treatment
Compound coenzyme
Compound coenzyme is the double heron exclusive varieties in Beijing is also the company's main varieties, belongs to the cardiovascular system, there are 24 provinces and cities be included in the medical insurance directory, the product is still in some provinces released adjuvant or monitored list. Compound coenzyme in 2015 sales of 4.625 billion yuan, the market share of 3.82%, up 2.37% from a year earlier.
Men and glucose injection
And men and glucose injection for occlusive cerebrovascular disease such as supplying the insufficiency, cerebral thrombosis, cerebral embolism and other ischemic vascular disease, is the core of the Victoria towers pharmaceutical products, occupies more than 99% of the market size and men glucose. Because of the influence of auxiliary medication, overall market size and men glucose in 2015 fell.
Large plant rhodiola injection
Big plant rhodiola injection jade SAN pharmaceutical manufacturer for tonghua, its functions of promoting blood circulation to remove blood stasis, hard is suitable for the treatment of stable coronary heart disease angina pectoris. In 2015 market size of eight.. 9.7 billion yuan, down 10.41% year-on-year in 2014. Kang edge, by contrast, big plant rhodiola capsule pharmaceutical market scale is only half of the large strain of rhodiola injection, but nearly three years in a continuous growth trend.
Systemic anti-infection drugs
Cephalosporins to lamictal
In 2015 to lamictal cephalosporin drugs drug market size is 4.106 billion yuan, a year-on-year growth of 18.29% in 2014. Annual sales of billions of manufacturers have characters group market share (38.53%), group method shows the market share (15.39%), guangdong people bond DPCL pharmaceutical market share (13.86%), South Korea (11.54%), hainan spirit kang pharmaceutical (6.60%), zhejiang, Beijing new pharmaceutical industry (5.50%), guangzhou baiyun mountain (3.54%).
Cefoperazone azole his temple
Cefoperazone in 2015 he azole drug temple market size is 2.881 billion yuan, a year-on-year growth of 5.70% in 2014. Annual sales of billions of manufacturers have a general sanyo market share (48.31%) in hainan, haikou, force pharmaceutical market share (37.27%), nolato, group market share (14.34%).
A oxime cephalosporin
A oxime is semi-synthetic cephalosporin of third generation cephalosporins, suitable for sensitive bacteria caused by respiratory system, urinary system, otolaryngology, and skin and soft tissue infection, etc. 2015 armor oxime cephalosporin drug market size is 2.828 billion yuan, a year-on-year growth of 27.35% in 2014. Annual sales of billions of manufacturers have a spike in zhejiang pharmaceutical market share (41.78%), that the guilin pharmaceutical (28.71%), hainan day bright pharmaceutical (20.30%), takeda pharmaceuticals (4.18%).
Ceftriaxone azole his temple
Ceftriaxone he thiazole ba for the fourth generation cephalosporins compound preparations, applicable to the treatment by sensitive to ceftriaxone unilaterally resistance, this compound of producing beta lactamase medium and severe infections caused by bacteria. He thiazole ba jotham sodium ceftriaxone sodium for injection is exclusive to haikou, force pharmaceutical varieties. 2015 drug market size is 1.095 billion yuan, a year-on-year growth of 19.64% in 2014.
flucloxacillin
Flucloxacillin belongs to the penicillin class anti-infection drugs, ranked tenth in the penicillin drugs. 2015 flucloxacillin drug market size is 821 million yuan, down 8.12% year-on-year in 2014. Annual sales of over billion manufacturer mainly shanxi cooperates group market share (72.34%), fosun group market share (21.51%).
And for the effect of
Add for as part of the quinolone anti-infection drugs, ranked no. 5 under the subclass. In 2015 for the effect of drug market size is 414 million yuan, a year-on-year growth of 57.5% in 2014. Top 10 brands (adr) of gatifloxacin only occupied the 54.38% of the overall market size, market concentration is higher.
Blood and hematopoietic system drugs
Invert sugar electrolyte
Invert sugar electrolyte ranked seventh in the blood and hematopoietic system medicine, is suitable for the need to supplement the oral route of water, energy and rehydration treatment of electrolyte of patients. Invert sugar electrolytes in 2015 drug market size is 2.7 billion yuan, a year-on-year growth of 20.54% in 2014. Major manufacturers have the Yangtze pharmaceutical market share (63.88%), the United States market share (36.12%) of the sport.
Polysaccharide iron
Polysaccharide iron belongs to anemia. 2015 polysaccharide iron drug market size is 598 million yuan, a year-on-year growth of 27.14% in 2014. Major manufacturers have schwarz market share (72.19%), Shanghai pharmaceutical group (27.77%).
Anti-tumor and immune modulators
Mannan peptide
At present, mannan peptide was 27 provinces and cities into medical insurance directory. The varieties belong to immune enhancer. In 2015, mannan peptide drug market size is 1.569 billion yuan, down 3.33% year-on-year in 2014. Major manufacturers have its group market share (55.62%), chengdu, pharmaceutical industry (41.39%).
BCG polysaccharide nucleic acid
2015 of BCG polysaccharide nucleic acid drug market size is 370 million yuan, a year-on-year growth of 43.24% in 2014. Main factory in hunan, biological market share (52.53%), zhejiang Wan Sheng pharmaceutical market share (37.06%).
IDA than star
IDA than star belongs to antineoplastic antibiotic drugs, is suitable for adult untreated acute myelogenous leukemia induced relapse and ease and adults induction ease of refractory acute myeloid leukemia, children and adults the second-line treatment of acute lymphocytic leukemia. IDA in 2015 than the star drug market size is 311 million yuan, down 8.35% year-on-year in 2014. The main manufacturer for Pfizer market share (57.57%), the sea is pharmaceutical industry (41.09%).
Respiratory medicine
Blood will be a net
Blood will net applies for infection induced systemic inflammatory response syndrome; Can also cooperate with the treatment of multiple organ dysfunction syndrome of viscera function is impaired. Blood will be a net injection of tianjin red sun pharmaceutical exclusive varieties, ranked tenth in the cough and cold medicines. Blood will be a net 2015 drug market size is 1.477 billion yuan, down 7.6% year-on-year in 2014
Eucalyptus twist pinic
Eucalyptus twist pinic mucous solubility expectorant, suitable for acute and chronic rhinitis, sinusitis; Acute and chronic bronchitis, pneumonia, lung abscess and bronchiectasis patients with respiratory diseases such as cough phlegm and chronic obstructive lung disease, pulmonary fungal infections, tuberculosis sputum ruled out. The Chinese medical association respiratory neurology, revision in the diagnosis and treatment of coughing guide (2015) included the eucalyptus twist pinic, will give the lemon eucalyptus pinic will enter the new medical insurance directory to increase. 2015 eucalyptus twist pinic drug market size is 562 million yuan, increased by 11.48% year-on-year. Currently only Beijing nine and pharmaceutical manufacturers.
Reproductive and urinary system of sex hormone drugs
Red flower ruyi
The efficacy of safflower ruyi pill for functions of analgesia, regulating menstruation, spot, traditional Chinese medicine is exclusive to Tibetan medicine varieties, into the possibility of the new medical insurance directory. |
